Skip to content

Opening book details…

About this Medicine article

702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study by Pal, S.; Tsao, C-K.; Suarez, C.; Kelly, W.; Pagliaro, L.; Vaishampayan, U.N.; Loriot, Y.; Srinivas, S.; McGregor, B.A.; Panneerselvam, A.; Curran, D.; Choueiri, T.K.; Agarwal, N. is a Medicine article available to read on EtoBox.

It is typically read by researchers, students, and practitioners in Medicine.

Author
Pal, S.; Tsao, C-K.; Suarez, C.; Kelly, W.; Pagliaro, L.; Vaishampayan, U.N.; Loriot, Y.; Srinivas, S.; McGregor, B.A.; Panneerselvam, A.; Curran, D.; Choueiri, T.K.; Agarwal, N.
Publisher
Oxford University Press; Elsevier BV (ISSN 0923-7534)
Published
2020
Field
Medicine (Health Sciences)

More by Pal, S.; Tsao, C-K.; Suarez, C.; Kelly, W.; Pagliaro, L.; Vaishampayan, U.N.; Loriot, Y.; Srinivas, S.; McGregor, B.A.; Panneerselvam, A.; Curran, D.; Choueiri, T.K.; Agarwal, N.

Browse all works by Pal, S.; Tsao, C-K.; Suarez, C.; Kelly, W.; Pagliaro, L.; Vaishampayan, U.N.; Loriot, Y.; Srinivas, S.; McGregor, B.A.; Panneerselvam, A.; Curran, D.; Choueiri, T.K.; Agarwal, N.